^
Association details:
| Biomarker: | CD5 positive |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | methotrexate (THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1762 Survival and CNS Relapse in Patients with CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study in Japan
Published date:
11/02/2023
Excerpt:
Our results confirmed favorable survival in the phase II study of DA-EPOCH-R/HD-MTX in clinical settings. DA-EPOCH-R/HD-MTX and IT MTX were associated with longer OS of patients with CD5+ DLBCL in our study cohort...
Secondary therapy:
DA-EPOCH-R
Source:
Title:
Long-term follow-up results of a phase II study of dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL).
Published date:
05/19/2021
Excerpt:
The 5-yr PFS and OS of pts with CD5+ ABC DLBCL (n = 39) were 72% and 74%, respectively….Both the survival benefit and safety of DA-EPOCH-R/HD-MTX were maintained during a 5-yr follow-up, indicating the excellent efficacy, and safety of this approach as a first-line therapy for CD5+ DLBCL.
Secondary therapy:
EPOCH-R
DOI:
10.1200/JCO.2021.39.15_suppl.7551
